文献速递浆细胞疾病

老年多发性骨髓瘤患者的治疗策略

How I treat multiple myeloma in geriatric patients.
PubMed 文献 · Blood · 2024-01-01

多发性骨髓瘤主要发生于老年患者,其治疗结局常因合并症和易发生治疗不良事件而受影响。本文通过2例临床实践病例,综述衰弱评估工具及老年初诊多发性骨髓瘤患者(含衰弱亚组)的现行治疗标准,并讨论个体化治疗及该人群的治疗前景。

要点

  • 衰弱评估在老年多发性骨髓瘤患者中应用日趋频繁,有助于指导治疗。
  • CD38单克隆抗体等免疫治疗及双特异性抗体等新兴免疫肿瘤药物将推动治疗进展。
  • 这些新药在老年及衰弱患者中的适用性是关键临床问题。

核心结论

  • 老年多发性骨髓瘤患者的治疗结局常因合并症和易发生治疗不良事件而受影响。
  • 衰弱评估的应用日趋频繁,在治疗持续进步的背景下将发挥作用。
  • CD38单克隆抗体及双特异性抗体等新药在老年和衰弱患者中的适用性是关键临床问题。

研究设计与样本

  • 本文为综述,基于临床实践中衍生的2例患者病例。
  • 综述内容包括现行衰弱评分及老年初诊多发性骨髓瘤患者(含衰弱亚组)的治疗标准。

主要发现

  • 老年多发性骨髓瘤患者的治疗结局常因合并症和易发生治疗不良事件而受影响。
  • 衰弱评估的应用日趋频繁。
  • CD38单克隆抗体免疫治疗及双特异性抗体等新兴免疫肿瘤药物将带来额外治疗进展。

临床怎么用

  • 本文讨论老年多发性骨髓瘤患者(含衰弱亚组)的个体化治疗方式。
  • 本文讨论该人群的治疗前景。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Multiple myeloma (MM) is primarily a disease of older patients. Until recently, geriatric aspects in the context of MM have been poorly investigated. Treatment outcomes for geriatric patients with MM are often compromised by comorbidities and an enhanced susceptibility to adverse events from therapy. Assessment of patient frailty has become more frequent and will be useful in the context of significant and continuous advances in therapy. The recent emergence of immunotherapy with CD38 monoclonal antibodies and upcoming immunooncology drugs, such as bispecific antibodies, will lead to additional therapeutic progress. The applicability of these new molecules to older and frail patients is a key clinical question. Here, we present 2 patient cases derived from clinical practice. We review current frailty scores and standards of care for older, newly diagnosed patients with MM, including frail subgroups, and discuss ways to tailor treatment, as well as treatment perspectives in this population.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Facon T, Leleu X, Manier S, et al. How I treat multiple myeloma in geriatric patients. Blood. 2024. PMID: 36693134. doi:10.1182/blood.2022017635

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。